

FOLD HERE

Radiation Safety Notice

This person has been treated with **BEXLUTRY™ (lutetium Lu 177 dotatate injection)**. Radioactivity from lutetium Lu 177 may still be present for up to 67 days after administration. Please refer to the information below and follow appropriate radiation precautions.

Patient name: _____

Hospital: _____

Treating physician: _____

City, State: _____

Administration date and time: _____

Administered activity (mCi or GBq): _____

Hospital contact:

Name: _____ Number: _____

Emergency contact:

Name: _____ Number: _____

Notes: _____

CURIUM

© 2026 Curium US LLC. Bexluty™, Curium™, and the Curium logo are trademarks of Curium US LLC. MAT-LD-US-00024 0526

Bexluty™
(lutetium Lu 177 dotatate injection)
for intravenous use

FOLD HERE

Radiation Safety Notice

This person has been treated with **BEXLUTRY™ (lutetium Lu 177 dotatate injection)**. Radioactivity from lutetium Lu 177 may still be present for up to 67 days after administration. Please refer to the information below and follow appropriate radiation precautions.

Patient name: _____

Hospital: _____

Treating physician: _____

City, State: _____

Administration date and time: _____

Administered activity (mCi or GBq): _____

Hospital contact:

Name: _____ Number: _____

Emergency contact:

Name: _____ Number: _____

Notes: _____

CURIUM

© 2026 Curium US LLC. Bexluty™, Curium™, and the Curium logo are trademarks of Curium US LLC. MAT-LD-US-00024 0526

Bexluty™
(lutetium Lu 177 dotatate injection)
for intravenous use

FOLD HERE

Radiation Safety Notice

This person has been treated with **BEXLUTRY™ (lutetium Lu 177 dotatate injection)**. Radioactivity from lutetium Lu 177 may still be present for up to 67 days after administration. Please refer to the information below and follow appropriate radiation precautions.

Patient name: _____

Hospital: _____

Treating physician: _____

City, State: _____

Administration date and time: _____

Administered activity (mCi or GBq): _____

Hospital contact:

Name: _____ Number: _____

Emergency contact:

Name: _____ Number: _____

Notes: _____

CURIUM

© 2026 Curium US LLC. Bexluty™, Curium™, and the Curium logo are trademarks of Curium US LLC. MAT-LD-US-00024 0526

Bexluty™
(lutetium Lu 177 dotatate injection)
for intravenous use

FOLD HERE

Radiation Safety Notice

This person has been treated with **BEXLUTRY™ (lutetium Lu 177 dotatate injection)**. Radioactivity from lutetium Lu 177 may still be present for up to 67 days after administration. Please refer to the information below and follow appropriate radiation precautions.

Patient name: _____

Hospital: _____

Treating physician: _____

City, State: _____

Administration date and time: _____

Administered activity (mCi or GBq): _____

Hospital contact:

Name: _____ Number: _____

Emergency contact:

Name: _____ Number: _____

Notes: _____

CURIUM

© 2026 Curium US LLC. Bexluty™, Curium™, and the Curium logo are trademarks of Curium US LLC. MAT-LD-US-00024 0526

Bexluty™
(lutetium Lu 177 dotatate injection)
for intravenous use